Eli Lilly Crescita futura

Future criteri di controllo 5/6

Eli Lilly prevede che gli utili e i ricavi cresceranno rispettivamente di 29.2% e 17.8% all'anno. Si prevede che l'EPS crescerà di 30% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 57.4% in 3 anni.

Informazioni chiave

29.2%

Tasso di crescita degli utili

30.0%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	23.8%
Tasso di crescita dei ricavi	17.8%
Rendimento futuro del capitale proprio	57.4%
Copertura analitica	Good
Ultimo aggiornamento	20 Nov 2024

Aggiornamenti recenti sulla crescita futura

Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Nov 01

Recent updates

Eli Lilly Stock: Unexpected Developments (Rating Downgrade)

Nov 21

Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Nov 01

Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

Sep 18

Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside

Sep 04

Eli Lilly: Tirzepatide's Winning Streak Continues

Aug 20

Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)

Aug 12

Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic

Aug 04

Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China

Jul 25

A Look At The Fair Value Of Eli Lilly and Company (NYSE:LLY)

Jul 16

Previsioni di crescita degli utili e dei ricavi

NYSE:LLY - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	69,955	24,933	18,304	22,415	26
12/31/2025	58,403	19,632	12,124	17,288	29
12/31/2024	45,654	11,307	8,684	11,901	28
9/30/2024	40,863	8,370	-1,744	6,032	N/A
6/30/2024	38,923	7,342	-2,024	4,510	N/A
3/31/2024	35,932	6,138	-2,292	3,676	N/A
12/31/2023	34,124	5,240	-1,548	4,240	N/A
9/30/2023	32,073	4,988	1,469	6,215	N/A
6/30/2023	29,516	6,498	3,307	6,242	N/A
3/31/2023	27,691	5,687	3,881	6,793	N/A
12/31/2022	28,541	6,245	4,696	7,586	N/A
9/30/2022	29,240	6,033	5,404	8,080	N/A
6/30/2022	29,071	5,692	4,950	7,494	N/A
3/31/2022	29,323	6,129	5,824	8,086	N/A
12/31/2021	28,318	5,582	5,604	7,366	N/A
9/30/2021	27,759	5,972	4,621	6,919	N/A
6/30/2021	26,726	6,071	4,837	7,095	N/A
3/31/2021	25,486	6,093	5,565	7,815	N/A
12/31/2020	24,540	6,194	4,471	6,500	N/A
9/30/2020	23,214	5,573	5,112	6,648	N/A
6/30/2020	22,950	5,618	4,890	6,352	N/A
3/31/2020	23,087	5,533	3,684	4,908	N/A
12/31/2019	22,320	4,638	3,483	4,837	N/A
9/30/2019	21,843	4,264	2,671	4,322	N/A
6/30/2019	21,673	4,103	3,324	4,933	N/A
3/31/2019	21,622	2,545	2,217	5,399	N/A
12/31/2018	21,493	3,151	2,506	5,525	N/A
9/30/2018	22,016	372	2,100	5,819	N/A
6/30/2018	22,368	-166	N/A	5,579	N/A
3/31/2018	22,607	1,074	N/A	5,712	N/A
12/31/2017	19,974	-86	N/A	5,616	N/A
9/30/2017	22,471	2,225	N/A	5,879	N/A
6/30/2017	22,005	2,447	N/A	5,659	N/A
3/31/2017	21,585	2,187	N/A	5,410	N/A
12/31/2016	21,222	2,738	N/A	4,851	N/A
9/30/2016	20,837	2,444	N/A	3,841	N/A
6/30/2016	20,605	2,466	N/A	3,284	N/A
3/31/2016	20,179	2,319	N/A	2,830	N/A
12/31/2015	19,959	2,408	N/A	2,965	N/A
9/30/2015	19,704	2,359	N/A	3,318	N/A
6/30/2015	19,620	2,059	N/A	3,905	N/A
3/31/2015	19,577	2,192	N/A	4,010	N/A
12/31/2014	19,616	2,391	N/A	4,458	N/A
9/30/2014	20,303	2,690	N/A	4,744	N/A
6/30/2014	21,200	3,392	N/A	5,045	N/A
3/31/2014	22,194	3,865	N/A	5,628	N/A
12/31/2013	23,113	4,685	N/A	5,735	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di LLY ( 29.2% all'anno) è superiore al tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Si prevede che gli utili di LLY ( 29.2% all'anno) cresceranno più rapidamente del mercato US ( 15.4% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di LLY cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di LLY ( 17.8% all'anno) crescerà più rapidamente del mercato US ( 9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di LLY ( 17.8% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di LLY sarà molto alto tra 3 anni ( 57.4 %).

Eli Lilly Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 18%

Price target increased by 7.4% to US$989

Consensus EPS estimates increase by 16%

Price target increased by 7.2% to US$987

Recent updates

Eli Lilly Stock: Unexpected Developments (Rating Downgrade)

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Eli Lilly and Company Announces Board Changes

Eli Lilly and Company Announces Positive Phase 2 Results for muvalaplin

Eli Lilly and Company Announces Detailed Results from the Phase 3 Survey-1 Three-Year Study

Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting

Eli Lilly and Company to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Third quarter dividend of US$1.30 announced

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges

Eli Lilly and Company Announces Positive Results from the TRAILBLAZER-ALZ 6 Phase 3B Study

Lilly's Mirikizumab Is First and Only IL23p19 Antagonist to Report Long-Term, Multi-Year, Sustained Efficacy and Safety Data for Both Ulcerative Colitis and Crohn's Disease

Eli Lilly and Company Declares Fourth-Quarter 2024 Dividend, Payable on December 10, 2024

Lilly's EBGLYSS (Lebrikizumab-Lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab

Eli Lilly Buy On Weakness Signal (Technical Analysis)

Consensus EPS estimates fall by 18%

Eli Lilly and Company to Report Q3, 2024 Results on Oct 30, 2024

Eli Lilly and Company Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn's Disease

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis

Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)

Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside

Eli Lilly: Tirzepatide's Winning Streak Continues

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Price target increased by 7.4% to US$989

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Consensus EPS estimates increase by 16%

Price target increased by 7.2% to US$987

Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Upcoming dividend of US$1.30 per share

Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China

A Look At The Fair Value Of Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita